

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

March 29, 2019

David Woodhouse Chief Executive Officer NGM Biopharmaceuticals, Inc. 333 Oyster Point Boulevard South San Francisco, CA 94080

Re: NGM Biopharmaceuticals, Inc.
Amendment No. 1 to Registration Statement on Form S-1
Filed March 25, 2019
File No. 333-227608

Dear Dr. Woodhouse:

We have reviewed your amended registration statement and have the following comment. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to the comment, we may have additional comments.

Amendment No. 1 to Form S-1

## Business

NGM313 Phase 1b Early Proof-of-Concept Clinical Trial, page 124

1. Your revised disclosures in this section refer to preliminary results for this early proof-of-concept trial, and also state that the study indicated that NGM313 is "safe." As previously stated in comment 14 of our prior comment letter dated September 7, 2018, safety determinations are solely within the authority of the FDA and comparable regulatory authorities. Accordingly, please revise your prospectus disclosure to remove the statement that your product candidate is safe.

David Woodhouse NGM Biopharmaceuticals, Inc. March 29, 2019 Page 2

You may contact Sasha Parikh at 202-551-3627 or Jim Rosenberg at 202-551-3679 if you have questions regarding comments on the financial statements and related matters. Please contact Dorrie Yale at 202-551-8776 or Erin Jaskot at 202-551-3442 with any other questions.

Sincerely,

Division of Corporation Finance Office of Healthcare & Insurance

cc: J. Carlton Fleming